Justin B. Klee - 04 Nov 2024 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Co-Chief Executive Officer, Director
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol
AMLX
Transactions as of
04 Nov 2024
Net transactions value
+$99,993
Form type
4
Filing time
06 Nov 2024, 19:24:39 UTC
Previous filing
02 Oct 2024
Next filing
08 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $99,993 +63,690 +2% $1.57 3,184,259 04 Nov 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (right to buy) Options Exercise $0 -63,690 -64% $0.000000 36,310 04 Nov 2024 Common Stock 63,690 $1.57 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested and exercisable.